Sectoral Asset Management’s ArriVent BioPharma AVBP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.64M Buy
87,343
+8,300
+11% +$254K 1.68% 18
2026
Q2
$2.75M Buy
79,043
+49,030
+163% +$1.45M 1.92% 16
2026
Q1
$720K Sell
30,013
-8,242
-22% -$186K 0.6% 44
2025
Q4
$770K Sell
38,255
-980
-2% -$20.4K 0.62% 44
2025
Q3
$724K Buy
39,235
+3,655
+10% +$71.8K 0.45% 59
2025
Q2
$775K Buy
35,580
+25,490
+253% +$529K 0.51% 51
2025
Q1
$187K Buy
+10,090
New +$247K 0.15% 73

Other funds holding AVBP

Sectoral Asset Management's AVBP Position: Q3 2026 in Review

Sectoral Asset Management increased its ArriVent BioPharma (AVBP) stake by 11% in Q3 2026, buying an estimated $254K and bringing the position to 87,343 shares worth $2.64M. The position accounts for 1.68% of the portfolio, ranked #18.

Sectoral Asset Management first reported a position in AVBP in Q1 2025 and has held it in 7 quarters since. The position peaked at $2.75M in Q2 2026. 151 funds tracked by Wall St. Rank hold AVBP as of Q3 2026.

  • Sectoral Asset Management held 87,343 shares of ArriVent BioPharma worth $2.64M as of Q3 2026.
  • Sectoral Asset Management bought 8,300 ArriVent BioPharma shares in Q3 2026, an estimated $254K.
  • ArriVent BioPharma made up 1.68% of Sectoral Asset Management's portfolio in Q3 2026, its #18 holding.
  • Sectoral Asset Management first reported a position in ArriVent BioPharma in Q1 2025 and has held it in 7 quarters since.
  • Sectoral Asset Management's ArriVent BioPharma position peaked at $2.75M in Q2 2026.
  • 151 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q3 2026.

Based on Sectoral Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.